SLC28A2

Across TCGA pan-cancer cohorts, SLC28A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC28A2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC28A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC28A2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

BLCA, GBM, and SKCM are the cancer types where SLC28A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.188	0.627	.015	12	view →
GBM	OS	Median	All	0.070	0.413	.001	9	view →
SKCM	DFS	Median	III,IV	0.124	0.605	<.001	6	view →
LGG	OS	Median	All	0.604	0.896	.028	4	view →
COAD	DFS	Median	All	1.000	0.680	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC28A2–BLCA (DFS)

Open the BLCA breakdown →